EUVIMEDEUVIMED entdecken
Crossref

Sesamin from Ginkgo biloba as a novel multi-target inhibitor of neuroinflammasomes: An integrated in silico discovery

Narmadhaa Sivagurunathan, Latchoumycandane Calivarathan, Rajesh Parsanathan

Pharmacological Research - Reports · 2026-12 · 6 · 100091

DOI: 10.1016/j.prerep.2026.100091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacological Research - Reports, 2026-12. Verfasst von Narmadhaa Sivagurunathan und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Anusandhan National Research Foundation, Indian Council of Medical Research, Council of Scientific and Industrial Research, India.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Förderung

  • Anusandhan National Research Foundation
  • Indian Council of Medical Research
  • Council of Scientific and Industrial Research, India
  • University Grants Commission
  • Department of Science and Technology, Ministry of Science and Technology, India

Zitieren

APA

Sivagurunathan, N., Calivarathan, L., & Parsanathan, R. (2026). Sesamin from Ginkgo biloba as a novel multi-target inhibitor of neuroinflammasomes: An integrated in silico discovery. Pharmacological Research - Reports, 6, 100091. https://doi.org/10.1016/j.prerep.2026.100091

Vancouver

Sivagurunathan N, Calivarathan L, Parsanathan R. Sesamin from Ginkgo biloba as a novel multi-target inhibitor of neuroinflammasomes: An integrated in silico discovery. Pharmacological Research - Reports. 2026;6:100091. doi:10.1016/j.prerep.2026.100091

BibTeX
@article{Sivagurunathan2026,
  author = {Sivagurunathan, Narmadhaa and Calivarathan, Latchoumycandane and Parsanathan, Rajesh},
  title = {Sesamin from Ginkgo biloba as a novel multi-target inhibitor of neuroinflammasomes: An integrated in silico discovery},
  journal = {Pharmacological Research - Reports},
  year = {2026},
  volume = {6},
  pages = {100091},
  doi = {10.1016/j.prerep.2026.100091}
}
Kostenlos starten →